Basic Fluorouracil Information

• INN (International Nonproprietary Name): Fluorouracil (also known as 5‑Fluorouracil, 5‑FU, Fluo​rouracilum, Fluorouracilo, Fluo​rouracil).
• Brand Names Available In Canada (English): Efudex (topical cream is noted as available in CAN in product listings); other brands and generics are listed internationally but specific Canadian brand listings beyond Efudex are not specified.
• ATC Code: L01BC02 (Antineoplastic Agents; Antimetabolites; Pyrimidine Analogues).
• Forms & Dosages: Injection vials commonly in 250 mg/5 mL, 500 mg/10 mL and 1 g/20 mL strengths; topical creams in 0.5%, 1%, 2%, 4% and 5% packaged in 20–40 g tubes; lotions/solutions such as 0.5% and 4% are also described.
• Manufacturers In Canada (English): Not specified in the raw product list; global manufacturers include Teva, Mylan, Sandoz, Pfizer, Medac and others.
• Registration Status In Canada (English): Not specified in the raw product list for a Canada-specific registration entry.
• OTC / Rx Classification: Prescription Only (Rx); fluorouracil is not available over-the-counter in any formulation.

Key Findings From Recent Trials

Major 2022–2025 Canadian & Global Studies

Patients and prescribers have been asking whether topical 5‑FU is better than cryotherapy for widespread sun damage and actinic keratosis.

Recent multicentre trials through 2024–25, including Canadian cohort analyses and international randomised controlled trials, increasingly show topical 5‑FU formulations between 0.5% and 5% outperform cryotherapy for field disease clearance.

Systemic oncology studies continuing into 2024 refine IV bolus and infusion schedules for colorectal and other solid tumours, with meta-analyses comparing IV 5‑FU regimens to capecitabine.

Main Outcomes

Topical fluorouracil showed superior lesion clearance in field cancerisation and sustained benefit at 12 months in multiple trials.

IV 5‑FU regimens provide comparable antitumour efficacy to capecitabine for certain colorectal protocols when used per protocol-specific dosing.

Adoption of topical 5‑FU in dermatology clinics increased in Canada as evidence mounted for field therapy effectiveness.

Safety Observations

Post‑market and trial safety signals remain consistent with established profiles.

Systemic administration is associated with predictable myelosuppression and gastrointestinal toxicity, often linked to DPYD (DPD) deficiency when present.

Topical use mainly causes local reactions such as erythema and desquamation, with low systemic absorption in standard courses.

Clinical Mechanism Of Action

Layman’s Explanation

People ask how 5‑FU works on skin lesions or tumours.

Fluorouracil is a chemotherapy medicine that slows or stops rapidly dividing cells from copying their DNA, so abnormal skin cells or cancer cells stop growing and are removed by the body.

Scientific Breakdown

Fluorouracil is a pyrimidine analogue in ATC class L01BC02 that becomes active inside cells as nucleotide metabolites.

The most critical active metabolite is fluorodeoxyuridine monophosphate (FdUMP), which binds and inhibits thymidylate synthase.

Intracellular Metabolism

Cellular enzymes convert 5‑FU into FdUMP and FUTP among other metabolites.

Dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene, is the main enzyme that catabolises 5‑FU.

DPYD deficiency reduces breakdown and causes accumulation of active metabolites, increasing systemic toxicity risk and prompting recommendations for pre‑treatment genotyping in high‑dose regimens.

DNA/RNA Disruption

FdUMP inhibits thymidylate synthase and lowers dTMP synthesis, producing “thymineless death” in rapidly dividing cells.

FUTP incorporates into RNA, disrupting processing and protein synthesis and contributing to cytotoxicity.

Topical formulations concentrate drug in the epidermis, producing local cytotoxic effects with generally minimal systemic exposure when used as directed.

Scope Of Approved & Off-Label Use

Health Canada Approvals (DIN-Based)

Health Canada classifies fluorouracil as prescription-only.

Topical and injectable formulations carry drug identification numbers (DINs) when registered, and Efudex cream is documented as a topical product present in Canadian listings.

Approved systemic indications cover a range of malignancies including colorectal, gastric and breast cancers, while topical indications include actinic keratosis and superficial basal cell carcinoma.

Notable Off-Label Trends In Canadian Practice

Dermatology clinics increasingly use topical 0.5–5% creams for field cancerisation beyond single lesions.

Compounding pharmacies prepare custom strengths on clinician request where a registered product does not match clinical needs.

In oncology, institutional protocols sometimes adapt scheduling or substitute oral capecitabine for IV 5‑FU within evidence-based frameworks and formulary rules.

Dosage Strategy

General Dosing Per Health Canada Monographs

IV regimens commonly cited include bolus schedules such as 12 mg/kg/day (maximum 800 mg/day) IV bolus for four days, followed by 6 mg/kg every other day in protocol variations.

Topical regimens are typically one to two times daily for two to six weeks depending on formulation and lesion location.

Common topical pack sizes include 20 g and 40 g tubes of creams such as Efudex in 2% and 5% strengths.

Condition-Specific Dosing Adjustments

Colorectal and gastrointestinal protocols are adjusted by body surface area and cycle-specific rules in oncology units.

Capecitabine is an oral prodrug alternative with its own dosing and monitoring needs and may be used as a substitute in outpatient settings.

Special populations require care: elderly patients need close monitoring rather than routine automatic dose reductions, children are specialist-only and off-label, and severe hepatic impairment usually warrants dose reduction.

DPYD/DPD deficiency requires dose modification or alternative therapy for systemic use and is a growing focus in pre‑treatment planning.

Safety Protocols

Contraindications (Canadian Advisories)

Absolute contraindications include known hypersensitivity to fluorouracil, pregnancy (teratogenic), and severe bone marrow suppression or severe active infection.

Relative cautions include significant hepatic or renal impairment, severe cardiac disease, and poor nutritional status.

Adverse Effects (Post-Market Reports)

Systemic treatment is associated with nausea, vomiting, diarrhoea, stomatitis, myelosuppression and photosensitivity among other effects.

Rare severe neurotoxicity has been reported, particularly in circumstances of DPYD deficiency.

Topical adverse effects are usually local and include erythema, burning, desquamation and pruritus at the application site.

Canadian practice emphasises DPYD consideration before high‑dose systemic plans, pregnancy testing for women of childbearing potential, and anticoagulant monitoring for patients on warfarin.

Adverse events should be reported to Health Canada’s Canada Vigilance Program and reviewed by institutional chemo-safety committees for injectable handling.

Interaction Mapping

Food Interactions Common In Canadian Diet

No direct food interactions are documented for fluorouracil itself.

However, treatment-related mucositis, vomiting or diarrhoea can affect intake of typical Canadian diets, so counsel on soft diets and hydration is practical.

Avoid applying topical cream on skin exposed to alcohol-based topical products that might increase irritation.

Drug Combinations Flagged By Health Canada

Fluorouracil potentiates warfarin and can increase INR; monitor anticoagulation closely when patients start or stop fluorouracil therapy.

Increased toxicity reports exist with allopurinol and metronidazole and interactions with phenytoin and other antiepileptics are possible.

Concomitant radiotherapy increases local reaction severity with topical 5‑FU, and combined systemic cytotoxics like oxaliplatin require protocol-specific monitoring.

Herbal products such as St John’s wort may complicate therapy indirectly through enzyme induction and should be reviewed during medication reconciliation.

Patient Experience Analysis

Canadian Survey Data

Surveys and clinic audits in Canada from 2022–25 show topical 5‑FU is rated effective but is sometimes stopped early because of local skin reactions and cosmetic concerns.

Oncology patients receiving IV 5‑FU describe predictable gastrointestinal and haematologic side effects, which can be minimised when DPYD testing is available and acted upon.

Access and cost concerns appear frequently, since topical creams may need special authority or private payment depending on provincial formularies.

Forum & Community Pharmacy Trends

Online forums reflect variable access, with patients sharing experiences about Efudex application, duration and how to manage desquamation.

Community pharmacies such as Shoppers and Rexall often provide counselling, help with coverage paperwork, and may stock Efudex or arrange specialty orders.

Pharmacist recommendations focus on clear written instructions, moisturiser strategies, sun avoidance and defined escalation paths for severe reactions.

Distribution & Pricing Landscape

National Pharmacy Chains

Topical creams and injectable vials circulate through hospital formularies and community chains including Shoppers, Rexall, Jean Coutu and London Drugs.

Branded items such as Efudex appear in product listings and generics are supplied by major manufacturers noted in international supply chains.

Online Pharmacy Availability & Provincial Restrictions

Canadian online pharmacies must comply with provincial dispensing rules and typically require a valid prescription for fluorouracil products.

Provincial formularies like Ontario Drug Benefit, BC PharmaCare and RAMQ determine public coverage and may require special authorizations for topical products.

Generic competition from manufacturers such as Teva, Sandoz and others has reduced unit costs for some formulations between 2022 and 2025.

Cross-Border US Comparisons

Some patients look to cross‑border purchases to reduce out-of-pocket costs, but importation risks and legal constraints apply.

Hospital‑supplied injectable 5‑FU is typically procured through institutional oncology budgets, while topical creams can require private payment if not covered.

In our online pharmacy, fluorouracil is available by prescription, with discreet delivery to Canada (English) in 5–14 days.

Alternative Options

Comparison Table Of DIN-Approved Alternatives

When fluorouracil is unsuitable or unavailable, clinicians consider alternatives based on indication and toxicity profile.

• Capecitabine (Xeloda) — oral prodrug of 5‑FU with comparable efficacy in many colorectal regimens but different adverse effects such as hand–foot syndrome and renal considerations.
• Gemcitabine (Gemzar) — another pyrimidine analogue used in pancreatic and lung cancers with a distinct myelosuppression profile.
• Tegafur-containing combinations (UFT, S‑1) — 5‑FU prodrugs used in some GI protocols with variable tolerability.
• Dermatology alternatives — imiquimod and photodynamic therapy offer non‑chemotherapeutic options for AK or superficial basal cell carcinoma with different cosmetic outcomes.

Pros And Cons Checklist

Capecitabine pros include oral convenience and outpatient use; cons include hand–foot syndrome risk and renal monitoring needs.

Gemcitabine offers activity in different tumour types but has a differing toxicity spectrum to weigh against patient comorbidities.

Topical non‑chemotherapy options may be preferred for cosmetic reasons, but clinicians consider efficacy, patient preference and formulary coverage when choosing therapy.

Regulatory Status

Health Canada Approval Process

Fluorouracil products are approved via New Drug Submissions or abbreviated pathways for generics and receive DINs when registered in Canada.

Approval decisions require evidence of safety, efficacy and product quality consistent with international regulators.

DIN And Bilingual Labelling Rules

Approved products in Canada must carry DINs and provide bilingual (English/French) patient information leaflets and pharmacovigilance instructions.

All dosage forms are prescription-only and injectable cytotoxics are handled under controlled hospital pharmacy distribution rules.

Labels include pregnancy contraindication language, warnings about DPYD-related toxicity, storage instructions and provincial reimbursement details when applicable.

Consolidated FAQ

Q1: Is 5‑FU cream available over-the-counter in Canada?

A1: No—fluorouracil formulations are prescription-only in Canada and require a prescription and DIN for dispensing.

Q2: Do I need genetic testing before 5‑FU chemotherapy?

A2: For high‑dose systemic regimens, DPYD (DPD) genotyping is increasingly recommended to reduce severe toxicity, though implementation varies by centre in Canada; ask your oncologist about local practice.

Q3: How do I apply topical 5‑FU and manage reactions?

A3: Apply as prescribed, commonly once or twice daily for two to six weeks; expect local erythema and desquamation and use moisturisers and sun avoidance as advised by your pharmacist or prescriber.

Q4: Will provincial plans cover topical 5‑FU?

A4: Coverage varies by province and plan and may require special authorization; community pharmacists can help with coverage applications and patient-assistance options.

Visual Guide

Clinicians and pharmacists often ask for simple visuals to explain dosing, coverage and purchase channels.

Suggested infographic elements include a dosing flowchart for topical strengths (0.5–5%) and typical durations of two to six weeks.

Another recommended graphic contrasts IV bolus schedules with capecitabine alternatives and highlights DPYD testing badges for systemic plans.

A provincial coverage map can summarise Ontario Drug Benefit, BC PharmaCare and RAMQ special-authority steps and show where topical creams are commonly covered or require prior approval.

Purchase-channel diagrams should show hospital procurement for injectables, community pharmacy dispensing for creams, online pharmacy constraints and cross‑border caveats.

All visuals should be accessible, bilingual and include safety icons for pregnancy contraindication and storage temperatures.

Storage & Transport

Canadian Household Guidelines

Injection vials should be stored at 20–25°C and protected from light; do not freeze.

Topical creams should be stored below 25°C, kept tightly closed and protected from moisture and heat.

Keep all medication out of reach of children and avoid applying topical cream to mucous membranes or broken skin beyond the target lesion.

Cold-Chain Storage Where Applicable

5‑FU injections do not generally require refrigeration if stored within recommended room temperatures, simplifying community dispensing across Canada’s climates.

Patients should avoid leaving creams or vials in hot vehicles and should follow pharmacy counselling for transport and accidental exposure procedures.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Pharmacists confirm the DIN, counsel on proper topical application (a thin film to the lesion, avoid healthy surrounding skin, wash hands after application) and provide printed bilingual instructions.

Sun avoidance, moisturiser use and recognition of severe local reactions are emphasised during counselling at community chains and specialty pharmacies.

For systemic care, pharmacists check dosing, renal and hepatic function, and coordinate DPYD testing where available.

Provincial Health Authority Guidance

Follow local chemo and dermatology guidance from provincial health authorities and adhere to formulary criteria and reporting pathways for adverse events.

Pharmacists assist with prior-authorizations on provincial plans such as Ontario Drug Benefit, BC PharmaCare and RAMQ and liaise with oncology clinics for smooth transitions of care.

Key safety checkpoints include pregnancy avoidance, early recognition of severe toxicity signs, and clear escalation instructions to the prescriber or emergency services.

Delivery Across Canada (English)

Concluding Practical Notes

Fluorouracil remains a WHO essential medicine with well-established topical and systemic roles in dermatology and oncology.

Prescribers and pharmacists in Canada should follow DIN labelling, consider DPYD testing for high‑dose systemic plans and counsel patients on expected topical reactions and safe storage.

Community pharmacies support coverage navigation and can help patients access registered products such as Efudex or arrange compounding when clinically appropriate.

Report adverse events to Canada Vigilance and use institutional safety committees for injectable handling and preparation queries.